We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Provides Final Update on Phase II Talazoparib Study
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity. The results were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Talazoparib is a poly ADP ribose polymerase (PARP) inhibitor, which is being investigated for cancer types with deficiencies in DNA damage repair (DDR).
Shares of Pfizer have underperformed the Zacks classified Large Cap Pharma industry so far this year. The stock has gained 0.2% during the period, while the broader industry witnessed an increase of 11.4%.
The phase II study evaluated safety and efficacy of talazoparib in patients with heavily pretreated gBRCA+ advanced breast cancer in two cohorts.
One cohort investigated talazoparib in patients who developed disease progression after responding to prior platinum-based chemotherapy, achieving a 21% objective response rate (ORR). Another cohort treated patients with at least three lines of non-platinum-based therapy and subsequently developed disease progression. This cohort achieved a 37% ORR.
The candidate is also being evaluated in an open-label, randomized phase III study, EMBRACA to compare the safety and efficacy of talazoparib versus protocol-specific physician's choice of chemotherapy in patients who have locally advanced and/or metastatic breast cancer with gBRCA+ mutations.
Talazoparib was added to Pfizer’s pipeline with the acquisition of cancer-focused biopharma company Medivation, Inc.
The breast cancer market provides immense commercial potential. We note that Novartis AG’s (NVS - Free Report) Kisqali has been recently approved while the FDA’s Oncologic Drugs Advisory Committee voted in favor of approval of Puma Biotechnology, Inc.’s (PBYI - Free Report) neratinib in May 2017. Moreover, Eli Lilly and Company’s (LLY - Free Report) abemaciclib is in late stages of development. The oncology market is attracting a lot of attention with several companies inking deals and working on bringing their candidates to this high-revenue potential market.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer Provides Final Update on Phase II Talazoparib Study
Pfizer Inc. (PFE - Free Report) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity. The results were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Talazoparib is a poly ADP ribose polymerase (PARP) inhibitor, which is being investigated for cancer types with deficiencies in DNA damage repair (DDR).
Shares of Pfizer have underperformed the Zacks classified Large Cap Pharma industry so far this year. The stock has gained 0.2% during the period, while the broader industry witnessed an increase of 11.4%.
The phase II study evaluated safety and efficacy of talazoparib in patients with heavily pretreated gBRCA+ advanced breast cancer in two cohorts.
One cohort investigated talazoparib in patients who developed disease progression after responding to prior platinum-based chemotherapy, achieving a 21% objective response rate (ORR). Another cohort treated patients with at least three lines of non-platinum-based therapy and subsequently developed disease progression. This cohort achieved a 37% ORR.
The candidate is also being evaluated in an open-label, randomized phase III study, EMBRACA to compare the safety and efficacy of talazoparib versus protocol-specific physician's choice of chemotherapy in patients who have locally advanced and/or metastatic breast cancer with gBRCA+ mutations.
Talazoparib was added to Pfizer’s pipeline with the acquisition of cancer-focused biopharma company Medivation, Inc.
The breast cancer market provides immense commercial potential. We note that Novartis AG’s (NVS - Free Report) Kisqali has been recently approved while the FDA’s Oncologic Drugs Advisory Committee voted in favor of approval of Puma Biotechnology, Inc.’s (PBYI - Free Report) neratinib in May 2017. Moreover, Eli Lilly and Company’s (LLY - Free Report) abemaciclib is in late stages of development. The oncology market is attracting a lot of attention with several companies inking deals and working on bringing their candidates to this high-revenue potential market.
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>